David Carberry Net Worth

The estimated Net Worth of David Carberry is at least $140 Thousand dollars as of 22 September 2021. Mr. Carberry owns over 50,000 units of Tyme Technologies Inc stock worth over $31,000 and over the last 7 years he sold TYME stock worth over $0. In addition, he makes $108,610 as Independent Director at Tyme Technologies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Carberry TYME stock SEC Form 4 insiders trading

David has made over 4 trades of the Tyme Technologies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of TYME stock worth $51,500 on 22 September 2021.

The largest trade he's ever made was buying 50,000 units of Tyme Technologies Inc stock on 22 September 2021 worth over $51,500. On average, David trades about 12,500 units every 69 days since 2017. As of 22 September 2021 he still owns at least 100,000 units of Tyme Technologies Inc stock.

You can see the complete history of Mr. Carberry stock trades at the bottom of the page.

David Carberry biography

David Carberry serves as Independent Director of the Company. He has been a member of our Board since March 2017. Mr. Carberry is a retired healthcare financial executive with over 40 years of experience in the industry. Most recently, from April 2012 to June 2016, Mr. Carberry was the Chief Financial Officer of Excellis Health Solutions, LLC, a consulting and software solutions company focused on the healthcare industry. Before that, Mr. Carberry was Chief Financial Officer of Aldagen, a biopharmaceutical company, from 2008 to 2011. Mr. Carberry also served in a number of financial oversight roles within Johnson & Johnson and related divisions between 1981 and 2008, including Vice President, Finance of Independence Technology L.L.C., Johnson & Johnson/Merck Consumer Pharmaceuticals, a joint venture, and Vice President, Finance of Johnson Health Care Systems, Inc., a healthcare account management and business services provider.

What is the salary of David Carberry?

As the Independent Director of Tyme Technologies Inc, the total compensation of David Carberry at Tyme Technologies Inc is $108,610. There are 7 executives at Tyme Technologies Inc getting paid more, with James Biehl having the highest compensation of $1,500,980.

How old is David Carberry?

David Carberry is 67, he's been the Independent Director of Tyme Technologies Inc since 2017. There are 3 older and 15 younger executives at Tyme Technologies Inc. The oldest executive at Tyme Technologies Inc is Gerald Sokol, 77, who is the Independent Director.

What's David Carberry's mailing address?

David's mailing address filed with the SEC is C/O TYME TECHNOLOGIES, INC., 1 PLUCKEMIN WAY - SUITE 103, BEDMINSTER, NJ, 07921.

Insiders trading at Tyme Technologies Inc

Over the last 7 years, insiders at Tyme Technologies Inc have traded over $11,656,990 worth of Tyme Technologies Inc stock and bought 384,831 units worth $412,502 . The most active insiders traders include Steve Hoffman, Michael Demurjian, and Douglas A Michels. On average, Tyme Technologies Inc executives and independent directors trade stock every 8 days with the average trade being worth of $15,104. The most recent stock trade was executed by Michael Demurjian on 6 September 2022, trading 160,000 units of TYME stock currently worth $40,000.

What does Tyme Technologies Inc do?

Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system.

With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.

Complete history of Mr. Carberry stock trades at Tyme Technologies Inc

Tyme Technologies Inc executives and stock owners

Tyme Technologies Inc executives and other stock owners filed with the SEC include:

• James Biehl,
  Chief Legal Officer and Corporate Secretary
• Michele Korfin,
  Chief Operating Officer
• Steve Hoffman,
  Chairman of the Board, Chief Executive Officer, Chief Science Officer
• Steven E. Hoffman,
  Co-Founder, Chairman & Chief Science Officer
• James Biehl J.D.,
  Chief Legal Officer & Sec.
• Dr. Jonathan M. Eckard,
  Chief Bus. Officer
• Richard Cunningham,
  CEO & Director
• David Carberry,
  Independent Director
• Donald Degolyer,
  Independent Director
• Gerald Sokol,
  Independent Director
• Timothy Tyson,
  Independent Director
• Douglas Michels,
  Independent Director
• Paul Sturman,
  Independent Director
• Jonathan Eckard,
  Chief Business Officer
• Giuseppe Del Priore,
  Chief Medical Officer
• Barbara Galaini,
  Principal Financial Officer, Principal Accounting Officer, Corporate Controller
• Frank L. Porfido,
  Chief Financial Officer
• Dr. Jan Marie-Albert Van Tornout M.D., M.Sc.,
  Acting Chief Medical Officer
• Dr. John M. Rothman,
  Exec. VP of Product Devel.
• John Zucaro P.E.,
  Sr. VP of CMC
• Tommy G Thompson,
  Director
• Christine D. Baker,
  Director
• John M. Rothman,
  EVP, Product Development
• Michael Demurjian,
  10% owner
• Ben R Taylor,
  President, CFO
• Tornout Jan M Van,
  Acting Chief Medical Officer
• Christopher F Brown,
  10% owner
• Frank L. Porfido,
  Chief Financial Officer
• Richard Anthony Cunningham,,
  Chief Executive Officer